Amneal Pharmaceuticals (NASDAQ:AMRX) Downgraded by Wall Street Zen to “Buy”

Amneal Pharmaceuticals (NASDAQ:AMRX) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Other analysts also recently issued reports about the stock. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Truist Financial upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. UBS Group began coverage on shares of Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $19.00 price objective for the company. Finally, Barclays upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.80.

Amneal Pharmaceuticals Trading Down 0.9%

NASDAQ:AMRX opened at $16.20 on Friday. The company has a market cap of $5.17 billion, a PE ratio of 42.63 and a beta of 1.30. Amneal Pharmaceuticals has a twelve month low of $7.66 and a twelve month high of $16.61. The company’s 50 day moving average is $13.03 and its two-hundred day moving average is $13.10.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The company had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. As a group, analysts expect that Amneal Pharmaceuticals will post 0.92 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 17.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Amneal Pharmaceuticals by 2.3% in the third quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock valued at $179,729,000 after purchasing an additional 403,582 shares during the period. Rubric Capital Management LP boosted its stake in Amneal Pharmaceuticals by 5.3% during the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after buying an additional 624,609 shares during the period. Dimensional Fund Advisors LP boosted its stake in Amneal Pharmaceuticals by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock worth $70,723,000 after buying an additional 81,546 shares during the period. Morgan Stanley boosted its stake in Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after buying an additional 1,315,018 shares during the period. Finally, Nantahala Capital Management LLC boosted its stake in Amneal Pharmaceuticals by 14.7% during the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock worth $35,333,000 after buying an additional 558,877 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.